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The reactivation of resolved hepatitis B virus
(HBV) infection is termed reverse seroconversion
(RS). HBV-RS is a complication after allogeneic stem
cell transplantation (SCT) in patients exposed to hepa-
titis B virus [1-4]. Recently, Onozawa et al [1] reported
that HBV vaccination is effective in the prevention of
HBV-RS after SCT, but there are limited data about
RS of hepatitis B in long-term SCT survivors. At our
institute, 15 of 103 patients with hematologic disorders
(14 leukemia or myelodysplastic syndrome [MDS], 1
severe apalstic anemia [AA]) receiving SCT from an
HLA identical sibling and surviving 3 or more years,
had a pretransplant resolved HBV infection (negative
HBsAg, positive anti-HBs and anti-HBc antibodies).
Twelve (median age 39.5 years) had received total
body irradiation (TBI)-based myeloablative SCT
followed by a T cell-depleted peripheral blood stem
cell transplantation (PBSCT), and 3 (median age 13
years) received a reduced-intensity regimen (RIC) of
fludarabine (Flu) and cyclophosphamide (Cy), fol-
lowed by PBSCT. All received cyclosporine (CsA) as
graft-versus-host disease (GVHD) prophylaxis. Eight
developed acute GVHD (aGVHD), and 12 developed
chronic GVHD (cGVHD), 8 of whom continued
immunosuppressive therapy (IST) 3 years ormore after
SCT. Serologic HBV markers were followed serially
(median follow-up 59 months; range: 40-113).
The probability of developing HBV-RS posttrans-
plant in recipients with resolved pretransplant HBV
infection was 30%. Five patients, 3 of whom had
received lamivudine, developed RS with reappearance
of HBsAg, 21-101 (median 31) months after SCT.
Three developed clinical hepatitis, which was success-
fully treated with lamivudine with a decrease of HBV
viral load after additional antiviral drugs in one. Of
the 10 patients who did not have RS, 6 were vaccinated
with HBV around 1 year posttransplant and 5 also
received lamivudine prophylaxis starting 3 months
posttransplant and continuing until anti-HBs antibody886becamepositive.Themedian length of lamivudine pro-
phylaxis time was 16.6 months. Six donors had been
vaccinated for HBV or had resolved HBV infection
pretransplant. Two recipients of these donors devel-
oped RS (Table 1). Fourteen (93%) patients are alive
(median follow-up 59 months). One patient with RS
died with relapsed myodysplastic syndrome (MDS),
59 months after SCT. There was no significant differ-
ence in the age, conditioning regimen, incidence of
aGVHD or cGVHD, nor duration of IST between
RS and non-RS patients.
The frequency of RS in our series was within the
range of 14%-50% reported [1-3,5]. However the me-
dian time to RS was longer (29 months versus 19
months; range: 6-72 months) [2,4]. Variations may be
attributable to different immunosuppressive regimens
or different incidence and severity of cGVHD. The
presence of cGVHD may result in earlier onset of RS
[3,6], but this was not a significant factor in our small
series. These results emphasize the need for continued
monitoring for HBV RS in patients at risk, especially
those receiving prolonged IST [2]. Prophylactic vacci-
nation with hepatitis B vaccine for patients with pre-
transplant resolved HBV infection is recommended
beginning 1 year posttransplant or after withdrawal of
IST [1], and hepatitis B vaccination of the donor may
help to prevent RS by passive transfer of immunity
against HBV to the SCT recipients [7], although nei-
ther priorHBV infection nor vaccination is completely
protective as we also found [6]. Therefore, the recipient
should also receive early posttransplant vaccination
following donor Hepatitis B vaccination. Although
lamivudine prophylaxis can prevent RS of HBV, it is
unknownatwhat stage prophylaxis can be discontinued
[8] and fatal fulminant hepatitis B has occurred after
withdrawal of lamivudine in SCT patients [8].
Since 2004, our policy for patients with positive
anti-HBc antibody before SCT, is to give lamivudine
100mg/day, within 3months posttransplant, vaccinate
around 1 year post-SCT, and continue lamivudine un-
til the anti-HBs antibody becomes positive. HBV reac-
tivation is monitored at regular intervals by testing
HBsAg, HBV-DNA, anti-HBs, and anti-HBc anti-
bodies. Antiviral therapy, for example, lamivudine
therapy, should be considered early in patients positive
for HBV-DNA; additionally, newer anti-HBV agents
like adefovir, entecavir, telbivudine, and tenofovir,
could be used if lamivudine resistance occurs.
In conclusion,RS ofHBVpost-SCT is a significant
long-term complication in patients with pretrans-
plant-resolved HBV infection. Our study emphasizes
the importance of posttransplant prophylaxis with
Table 1. Comparison of Patients with and without HBV-RS
Variable With HBV-RS Without HBV-RS
P ValueCases 5 (33%) 10 (67%)
Age in years (median, range) 45 (10-46) 32(13-56) .83
Conditioning regimen
Myeloablative 4/5 (80%) 8/10 (80%) 1.0
Reduced intensity 1/5 (20%) 2/10 (20%) 1.0
aGVHD 1/5 (20%) 7/10 (70%) .12
Grade II-IV aGVHD 1/5 (20%) 1/10 (10%) 1.0
cGVHD 4/5 (80%) 8/10 (80%) 1.0
Extensive cGVHD 1/5 (20%) 1/10 (10%) 1.0
IST for cGVHD >3 years 3/5 (60%) 5/10 (50%) 1.0
Lamivudine treatment 3/5 (60%) —
Lamivudine prophylaxis* 0 5/10 (50%)
HBV vaccine after SCT 0 6/10 (60%)
Donors with
vaccination of HBV
1/5 (20%) 1/10 (10%) 1.0
Donors with
resolved HBV infection
1/5 (20%) 3/10 (30%) 1.0
RS of HBV in months
(median, range)
31 (21-101) —
Follow-up in months
(median, range)
59 (55-105) 57.5 (40-113) .37
RS indicates reverse seroconversion; HBV, hepatitis B virus; aGVHD,
acute graft-versus- host disease; cGVHD, chronic graft-versus-host dis-
ease; IST, immunosuppressive therapy; SCT, stem cell transplantation.
*Also received HBV vaccination.
Biol Blood Marrow Transplant 15:886-891, 2009 887Letters to the Editorlamivudine, hepatitis B vaccine, long-term hepatitis B
serologic monitoring, and prompt initiation of lamivu-
dine treatment if HBV-RS occurs.REFERENCES
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Fatal Hyperacute Graft-
versus-Host Disease following
Denileukin Diftitox Treatment
for Recurrent T Cell
Lymphoma after Allogeneic
Stem Cell Transplantation
Acute graft-versus-host disease (aGVHD) causes
serious morbidity and mortality after allogeneic hema-
topoietic stem cell transplantation (HSCT). Outcomes
of therapy with glucocorticoids may be suboptimal,
and patients who do not respond to steroids have
a poor prognosis. The pathogenesis of aGVHD
involves a cytokine storm induced by pretransplanta-
tion conditioning along with dendritic cell and T cell
activation, leading to up-regulation of inflammatory
cytokines and alloreactive donor lymphocytes that
attack recipient tissues [1]. Interleukin (IL)-2 is a T
cell–derived cytokine that plays a central role in im-
mune responses by inducing activated T cell prolifer-
ation, facilitating B cell activation and proliferation,
and modulating macrophage function.
Denileukin diftitox (Ontak; Eisai Medical Re-
search, Seragen, Inc, Hopkinton, MA, License #1258)
is a recombinant fusionprotein that preferentially binds
with high affinity to T cells expressing IL-2 receptors
(CD25) [2]. Some previous reports have indicated
that denileukin diftitox depletes the CD41/CD25high
subset of T regulatory (Treg) cells, a mechanism that
has been implicated in the drug’s activity against
tumors [3]. The same subset of Treg cells suppresses
alloreactive T cells and is an important regulator of
the GVHD response [4]. It has been hypothesized
that selective binding and depletion of activated T cells
